Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT04345406
Starting soon Phase 3

Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19

NCT04345406 · tracked via the Priya Life Science Egypt tracker
Sponsor
Tanta University
Phase
Phase 3
Started
2020-04-15
Last updated
2020-04-14

Condition(s) studied

COVID

Investigational drug(s) / intervention(s)

ACEIs →Conventional treatment →

ACEIs: Captopril or enalapril

Conventional treatment: alexoquine

Study summary

ACEIs as treatment for COVID19

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients infected with covid 19 Exclusion Criteria: * allergy or contraindications to the drug

Primary outcome measure(s)

  • number of patients with virological cure — 6 months
    number of patients with virological cure

Trial sites (1)

FacilityCityRegionStatus
Tanta University Tanta Egypt

More Tanta University trials in Egypt

Carotid Ultrasound for Post-Spinal Anesthesia Hypotension in Elderly Hip Surgery Starting soon
Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients Recruiting
Pelvic Floor Therapies for Lifelong Premature Ejaculation Recruiting
Carotid Artery Corrected Flow Time and Inferior Vena Cava Collapsibility Index for Prediction of Hypotension After Induction of General Anesthesia in Geriatric Patients Undergoing Elective Surgery Recruiting
Laparoscopic Management of Gastroesophageal Reflux Disease in Children Recruiting

Other trials for the same condition

Novel Regimens in COVID-19 Treatment Recruiting
The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04345406 on ClinicalTrials.gov ↗ ← All trials in Egypt